PCSA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.3M
-29.9%
3.3M
-10.0%
3.7M
+6.1%
3.5M
-11.7%
4.0M
R&D
649.9K
-64.1%
1.8M
-14.4%
2.1M
+27.2%
1.7M
-32.1%
2.4M
SG&A
1.7M
+10.8%
1.5M
-4.2%
1.6M
-13.1%
1.8M
+21.5%
1.5M
Operating Income
-2336138
+29.9%
-3331214
+10.0%
-3701889
-6.1%
-3488843
+11.7%
-3950783
EBITDA
-2335837
+29.9%
-3330913
+10.0%
-3701588
-6.1%
-3488542
+11.7%
-3950482
Net Income
-3265494
+3.3%
-3377179
-0.5%
-3358938
+2.3%
-3436573
+12.6%
-3933918
EPS (Basic)
$-1.19
+7.8%
$-1.29
$-1.75
+72.0%
$-6.26
EPS (Diluted)
$-1.19
+7.8%
$-1.29
$-1.75
+72.0%
$-6.26
Shares (Diluted)
2.8M
+4.9%
2.6M
1.9M
+202.3%
628.8K
Processa Pharmaceuticals, Inc. Common (PCSA) — Financials